The $400 Billion Patent Cliff: A Technical Playbook for Pharma IP Teams and Portfolio Managers
The patent cliff bearing down on pharma between now and 2030 is not a scheduling problem. It is a structural […]
Biopharma Sales Forecasting in the Value-Based Era: The Complete Analyst’s Playbook
For pharma IP teams, portfolio managers, R&D leads, and institutional investors navigating the post-IRA, outcomes-contingent revenue landscape. The numbers are
Biopharma Sales Forecasting in the Value-Based Era: The Complete Analyst’s Playbook Read Post »
Drug Patent Valuation: The 8-Factor Framework That Separates $50M Assets from $50B Ones
A drug patent is not a legal document. It is a financial instrument — one whose value fluctuates from zero
Drug Patent Valuation: The 8-Factor Framework That Separates $50M Assets from $50B Ones Read Post »
Cross-Border Pharma Licensing: The Patent Data Playbook for IP Teams and Portfolio Managers
The global biopharmaceutical deal machine ran at record velocity in 2024. China’s out-licensing deal value hit an estimated $47 billion,
US vs EU Pharma Patent Strategy: The Complete Competitive Intelligence Guide
Every year, pharmaceutical companies forfeit billions in recoverable IP value not because their science failed, but because their patent strategy
US vs EU Pharma Patent Strategy: The Complete Competitive Intelligence Guide Read Post »
Pharma Patent Cliff Models That Actually Predict Stock Performance
Between 2025 and 2030, an estimated $200-300 billion in branded drug sales globally will lose patent protection. That figure covers
Pharma Patent Cliff Models That Actually Predict Stock Performance Read Post »
Drug Patent Portfolio ROI: The Complete Optimization Playbook for Pharma IP Teams
The average capitalized cost to develop a new drug now exceeds $2.23 billion. The effective market exclusivity that investment buys,
Drug Patent Portfolio ROI: The Complete Optimization Playbook for Pharma IP Teams Read Post »
How to Defend a Biologic Franchise: The Complete IP, Legal, and Commercial Playbook Against Biosimilar Competition
The loss of exclusivity for a blockbuster biologic is no longer a theoretical risk management exercise. It is a discrete,
Excipient Leads from Drug Reformulation: The Complete Intelligence Playbook for Pharma Suppliers
Every year, pharmaceutical companies quietly authorize hundreds of millions of dollars in new formulation work before a single press release
